Boston Scientific (NYSE:BSX) Given New $56.00 Price Target at BTIG Research

Boston Scientific (NYSE:BSX) had its target price reduced by BTIG Research from $60.00 to $56.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. BTIG Research’s price target would indicate a potential upside of 24.44% from the company’s previous close.

BSX has been the subject of a number of other research reports. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Mizuho decreased their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Jefferies Financial Group cut their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $71.46.

Boston Scientific Trading Down 5.9%

BSX stock opened at $45.00 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $65.22 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.10 and a beta of 0.57. The business has a fifty day simple moving average of $47.04 and a 200-day simple moving average of $55.18. Boston Scientific has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the firm earned $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts expect that Boston Scientific will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter worth $26,000. Main Street Financial Solutions LLC raised its holdings in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its holdings in Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC boosted its stake in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing, shipping and other global operations are recovering, which could limit the disruption’s duration. The company also continues to point to multiple product launches and cost savings as potential longer-term growth drivers. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided replacement targets for its third-quarter or full-year 2026 outlook. Investors will likely focus on the pace of operational recovery and the size of the eventual revenue and profit shortfall. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: The cyberattack disrupted manufacturing and order shipments worldwide, creating a material expected impact on third-quarter and full-year 2026 results. The warning raises the risk of lower sales, reduced operating leverage and an earnings miss relative to prior guidance. Boston Scientific Won’t Meet Guidance Due to Cyberattack
• Negative Sentiment: Beyond the immediate cyberattack effects, analysts noted pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses, weakening the company’s 2026 growth outlook. That near-term uncertainty outweighs the longer-term benefit expected from new product launches and cost initiatives. Boston Scientific’s 2026 Growth Outlook Weakens

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.